Literature DB >> 1183220

A double-blind controlled trial of 'Gaviscon' in patients with symptomatic gastro-oesophageal reflux.

D E Barnardo, M Lancaster-Smith, I D Strickland, J T Wright.   

Abstract

In a double-blind trial in 26 patients with symptomatic gastro-oesophageal reflux, the alginate/effervescent/antacid compound 'Gaviscon' was compared with antacid containing placebo similarly formulated. Retrosternal pain after meals and at night was significantly reduced whilst patients were taking 'Gaviscon' and the beneficial effects lasted for many weeks after discontinuation of the active preparation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1183220     DOI: 10.1185/03007997509114793

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  3 in total

Review 1.  Alginate therapy is effective treatment for GERD symptoms: a systematic review and meta-analysis.

Authors:  D A Leiman; B P Riff; S Morgan; D C Metz; G W Falk; B French; C A Umscheid; J D Lewis
Journal:  Dis Esophagus       Date:  2017-05-01       Impact factor: 3.429

Review 2.  Antacids. Indications and limitations.

Authors:  C K Ching; S K Lam
Journal:  Drugs       Date:  1994-02       Impact factor: 9.546

3.  Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.

Authors:  Denis Pouchain; Marc-André Bigard; François Liard; Marc Childs; Annick Decaudin; Donna McVey
Journal:  BMC Gastroenterol       Date:  2012-02-23       Impact factor: 3.067

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.